NCT06773455View on ClinicalTrials.gov

Tralokinumab for Dupilumab Failures

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

April 1, 2025

Conditions
Atopic Dermatitis
Interventions
DRUG

tralokinumab

600mg at week 0 followed by 300mg Q2W for 24 weeks

Trial Locations (1)

08520

Psoriasis Treatment Center of New Jersey, East Windsor

Sponsors

Collaborators (1)

LEO Pharma
All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

lead

Psoriasis Treatment Center of Central New Jersey

OTHER

NCT06773455 - Tralokinumab for Dupilumab Failures | Biotech Hunter | Biotech Hunter